creating a new prophylaxis against a virus that in many cases is no worse than a common cold. But in the very young and the elderly, RSV can turn into a serious infection and prove fatal. Hot on GSK’s heels however was Pfizer, which just several weeks later nabbed an ap...
targets and inhibits tumor angiogenesis-inducing VEGFR2. PharmAbcine is conducting a Phase 2 clinical trial on olinvacimab in patients with Avastin-refractory rGBM in the U.S. andAustralia. In addition, Phase1btrials on olinvacimab plus PD-1 antibody Keytruda ...